Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/31755
ARE RESPIRATORY COMPLICATIONS OF PLASMODIUM VIVAX MALARIA AN UNDERESTIMATED PROBLEM?
Author
Affilliation
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Universidad Nacional Autónoma de Honduras. Microbiology Research Institute. Tegucigalpa, Honduras.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Universidad Nacional Autónoma de Honduras. Microbiology Research Institute. Tegucigalpa, Honduras.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
ISGlobal. Barcelona Centre for International Health Research. Barcelona, Spain / Hospital Clínic-Universitat de Barcelona. Barcelona, Spain / Institució Catalana de Recerca i Estudis Avançats. Barcelona, Spain / University of Barcelona. Hospital Sant Joan de Déu. Pediatrics Department. Pediatric Infectious Diseases Unit. Barcelona. Spain / Universidad Europea de Madrid. Madrid, Spain.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil / Fundação Oswaldo Cruz. Instituto de Pesquisas Leônidas e Maria Deane. Manaus, AM, Brasil.
Universidad Nacional Autónoma de Honduras. Microbiology Research Institute. Tegucigalpa, Honduras.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Universidad Nacional Autónoma de Honduras. Microbiology Research Institute. Tegucigalpa, Honduras.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
ISGlobal. Barcelona Centre for International Health Research. Barcelona, Spain / Hospital Clínic-Universitat de Barcelona. Barcelona, Spain / Institució Catalana de Recerca i Estudis Avançats. Barcelona, Spain / University of Barcelona. Hospital Sant Joan de Déu. Pediatrics Department. Pediatric Infectious Diseases Unit. Barcelona. Spain / Universidad Europea de Madrid. Madrid, Spain.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil.
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Manaus, AM, Brasil / Universidade do Estado do Amazonas. Manaus, AM, Brasil / Fundação Oswaldo Cruz. Instituto de Pesquisas Leônidas e Maria Deane. Manaus, AM, Brasil.
Abstract
Background: Respiratory complications are uncommon, but often life-threatening features of Plasmodium vivax
malaria. This study aimed to estimate the prevalence and lethality associated with such complications among P. vivax malaria patients in a tertiary hospital in the Western Brazilian Amazon, and to identify variables associated with severe respiratory complications, intensive care need and death. Medical records from 2009 to 2016 were reviewed aiming to identify all patients diagnosed with P. vivax malaria and respiratory complications. Prevalence, lethality and risk factors associated with WHO defned respiratory complications, intensive care need and death were assessed. Results: A total of 587 vivax malaria patients were hospitalized during the study period. Thirty (5.1%) developed respiratory complications. Thirteen (43.3%) developed severe respiratory complications, intensive care was required for 12 (40%) patients and 5 (16.6%) died. On admission, anaemia and thrombocytopaenia were common fndings, whereas fever was unusual. Patients presented diferent classes of parasitaemia and six were aparasitaemic on admission. Time to respiratory complications occurred after anti-malarials administration in 18 (60%) patients and progressed very rapidly. Seventeen patients (56.7%) had comorbidities and/or concomitant conditions, which were signifcantly associated to higher odds of developing severe respiratory complications, need for intensive care and death (p < 0.05). Conclusion: Respiratory complications were shown to be associated with signifcant mortality in this population. Patients with comorbidities and/or concomitant conditions require special attention to avoid this potential life-threatening complication.
Share